Abcuro Inc, a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, has announced the appointment of George Eldridge as chief financial officer.
George brings more than 30 years of executive leadership experience in finance and business operations across the biotechnology industry.
Alex Martin, chief executive officer, said: “George brings industry-leading financial expertise that will be essential to Abcuro as we prepare for a pivotal clinical data readout for our lead asset, ulviprubart. We are delighted to further strengthen our leadership team with George’s appointment and look forward to working with him and build on our strong financial position to advance ulviprubart.”
George has more than three decades of experience fundraising, taking companies public, facilitating mergers and acquisitions, and establishing critical financial operations throughout his career.
He most recently served as CFO of Aerovate Therapeutics, notably guiding the company through its successful initial public offering (IPO) in 2021 and subsequent reverse merger with Jade Biosciences in 2025.
George said: “I am honoured to join Abcuro and look forward to working closely with the leadership team to deliver on our mission to develop potentially life-transforming treatments for patients with devastating diseases like IBM.”
